Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer
Endometrial cancer (EC) has a poor prognosis due to drug resistance. We evaluated the safety and efficacy of adjuvant combination chemotherapy with docetaxel plus cisplatin ((DP) docetaxel, 70 mg/m(2); cisplatin, 60 mg/m(2); every 28 days) in EC patients at intermediate-risk (IR) or high-risk (HR) f...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2016-07, Vol.36 (7), p.3725 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 7 |
| container_start_page | 3725 |
| container_title | Anticancer research |
| container_volume | 36 |
| creator | Miyahara, Daisuke Katsuta, Takahiro Maehara, Miyako Takahashi, Yoko Fukagawa, Satoshi Miyata, Kouhei Kiyoshima, Chihiro Yotsumoto, Fusanori Anan, Haruchika Miyamoto, Shingo |
| description | Endometrial cancer (EC) has a poor prognosis due to drug resistance.
We evaluated the safety and efficacy of adjuvant combination chemotherapy with docetaxel plus cisplatin ((DP) docetaxel, 70 mg/m(2); cisplatin, 60 mg/m(2); every 28 days) in EC patients at intermediate-risk (IR) or high-risk (HR) for recurrence.
Sixty-four patients diagnosed with EC were enrolled. Stage-I, -II, -III and -IV disease was noted in 23, 7, 28 and 6 patients, respectively. Histopathological analyses revealed that 56, 3, 1 and 4 patients had endometrioid, serous, clear-cell or "other" types of carcinoma. Grade-3/4 hematologic toxicities were found at 80% and 95% in patients in IR and HR groups, respectively. In IR and HR groups, mean progression-free (PFS) survival was 69.5 and 29.5, while overall survival (OS) was 59.6 and 47.5 months, respectively.
DP may be clinically safe and useful treatment for EC. |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_27354646</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>27354646</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-21d1f0648d849d61cefc91667de6adb8cfb259182ee46586a49db1923cebdc0e3</originalsourceid><addsrcrecordid>eNo1j99KwzAchYMgbk5fQfICgSZp0-Ry1OoGAwX1eqTJLxrXpiVJwb29xT9w4Ls5fJxzgda0VpTUFS9W6Dqlz6IQQkl-hVas5lUpSrFGpxftIJ-xDhZvQ_Ykz8MYcescmJzw6PD9aCDrL-jxcz8n3Pg09Tr7gJfsQ4Y4gPU6A_lx7Pz7B4k-nXAb7DhAjl73uNHBQLxBl073CW7_uEFvD-1rsyOHp8d9sz2QiVGaCaOWukKU0spSWUENOKOoELUFoW0njetYpahkAKWopNBLq6OKcQOdNQXwDbr79U5zt4w7TtEPOp6P_6_5N-kdU-E</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Miyahara, Daisuke ; Katsuta, Takahiro ; Maehara, Miyako ; Takahashi, Yoko ; Fukagawa, Satoshi ; Miyata, Kouhei ; Kiyoshima, Chihiro ; Yotsumoto, Fusanori ; Anan, Haruchika ; Miyamoto, Shingo</creator><creatorcontrib>Miyahara, Daisuke ; Katsuta, Takahiro ; Maehara, Miyako ; Takahashi, Yoko ; Fukagawa, Satoshi ; Miyata, Kouhei ; Kiyoshima, Chihiro ; Yotsumoto, Fusanori ; Anan, Haruchika ; Miyamoto, Shingo</creatorcontrib><description>Endometrial cancer (EC) has a poor prognosis due to drug resistance.
We evaluated the safety and efficacy of adjuvant combination chemotherapy with docetaxel plus cisplatin ((DP) docetaxel, 70 mg/m(2); cisplatin, 60 mg/m(2); every 28 days) in EC patients at intermediate-risk (IR) or high-risk (HR) for recurrence.
Sixty-four patients diagnosed with EC were enrolled. Stage-I, -II, -III and -IV disease was noted in 23, 7, 28 and 6 patients, respectively. Histopathological analyses revealed that 56, 3, 1 and 4 patients had endometrioid, serous, clear-cell or "other" types of carcinoma. Grade-3/4 hematologic toxicities were found at 80% and 95% in patients in IR and HR groups, respectively. In IR and HR groups, mean progression-free (PFS) survival was 69.5 and 29.5, while overall survival (OS) was 59.6 and 47.5 months, respectively.
DP may be clinically safe and useful treatment for EC.</description><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 27354646</identifier><language>eng</language><publisher>Greece</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Endometrioid - drug therapy ; Carcinoma, Endometrioid - mortality ; Cisplatin - administration & dosage ; Disease-Free Survival ; Drug Administration Schedule ; Endometrial Neoplasms - drug therapy ; Endometrial Neoplasms - mortality ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Proportional Hazards Models ; Retrospective Studies ; Risk ; Taxoids - administration & dosage ; Treatment Outcome</subject><ispartof>Anticancer research, 2016-07, Vol.36 (7), p.3725</ispartof><rights>Copyright© 2016 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27354646$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Miyahara, Daisuke</creatorcontrib><creatorcontrib>Katsuta, Takahiro</creatorcontrib><creatorcontrib>Maehara, Miyako</creatorcontrib><creatorcontrib>Takahashi, Yoko</creatorcontrib><creatorcontrib>Fukagawa, Satoshi</creatorcontrib><creatorcontrib>Miyata, Kouhei</creatorcontrib><creatorcontrib>Kiyoshima, Chihiro</creatorcontrib><creatorcontrib>Yotsumoto, Fusanori</creatorcontrib><creatorcontrib>Anan, Haruchika</creatorcontrib><creatorcontrib>Miyamoto, Shingo</creatorcontrib><title>Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Endometrial cancer (EC) has a poor prognosis due to drug resistance.
We evaluated the safety and efficacy of adjuvant combination chemotherapy with docetaxel plus cisplatin ((DP) docetaxel, 70 mg/m(2); cisplatin, 60 mg/m(2); every 28 days) in EC patients at intermediate-risk (IR) or high-risk (HR) for recurrence.
Sixty-four patients diagnosed with EC were enrolled. Stage-I, -II, -III and -IV disease was noted in 23, 7, 28 and 6 patients, respectively. Histopathological analyses revealed that 56, 3, 1 and 4 patients had endometrioid, serous, clear-cell or "other" types of carcinoma. Grade-3/4 hematologic toxicities were found at 80% and 95% in patients in IR and HR groups, respectively. In IR and HR groups, mean progression-free (PFS) survival was 69.5 and 29.5, while overall survival (OS) was 59.6 and 47.5 months, respectively.
DP may be clinically safe and useful treatment for EC.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma, Endometrioid - drug therapy</subject><subject>Carcinoma, Endometrioid - mortality</subject><subject>Cisplatin - administration & dosage</subject><subject>Disease-Free Survival</subject><subject>Drug Administration Schedule</subject><subject>Endometrial Neoplasms - drug therapy</subject><subject>Endometrial Neoplasms - mortality</subject><subject>Female</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Middle Aged</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk</subject><subject>Taxoids - administration & dosage</subject><subject>Treatment Outcome</subject><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j99KwzAchYMgbk5fQfICgSZp0-Ry1OoGAwX1eqTJLxrXpiVJwb29xT9w4Ls5fJxzgda0VpTUFS9W6Dqlz6IQQkl-hVas5lUpSrFGpxftIJ-xDhZvQ_Ykz8MYcescmJzw6PD9aCDrL-jxcz8n3Pg09Tr7gJfsQ4Y4gPU6A_lx7Pz7B4k-nXAb7DhAjl73uNHBQLxBl073CW7_uEFvD-1rsyOHp8d9sz2QiVGaCaOWukKU0spSWUENOKOoELUFoW0njetYpahkAKWopNBLq6OKcQOdNQXwDbr79U5zt4w7TtEPOp6P_6_5N-kdU-E</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Miyahara, Daisuke</creator><creator>Katsuta, Takahiro</creator><creator>Maehara, Miyako</creator><creator>Takahashi, Yoko</creator><creator>Fukagawa, Satoshi</creator><creator>Miyata, Kouhei</creator><creator>Kiyoshima, Chihiro</creator><creator>Yotsumoto, Fusanori</creator><creator>Anan, Haruchika</creator><creator>Miyamoto, Shingo</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20160701</creationdate><title>Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer</title><author>Miyahara, Daisuke ; Katsuta, Takahiro ; Maehara, Miyako ; Takahashi, Yoko ; Fukagawa, Satoshi ; Miyata, Kouhei ; Kiyoshima, Chihiro ; Yotsumoto, Fusanori ; Anan, Haruchika ; Miyamoto, Shingo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-21d1f0648d849d61cefc91667de6adb8cfb259182ee46586a49db1923cebdc0e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma, Endometrioid - drug therapy</topic><topic>Carcinoma, Endometrioid - mortality</topic><topic>Cisplatin - administration & dosage</topic><topic>Disease-Free Survival</topic><topic>Drug Administration Schedule</topic><topic>Endometrial Neoplasms - drug therapy</topic><topic>Endometrial Neoplasms - mortality</topic><topic>Female</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Middle Aged</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk</topic><topic>Taxoids - administration & dosage</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Miyahara, Daisuke</creatorcontrib><creatorcontrib>Katsuta, Takahiro</creatorcontrib><creatorcontrib>Maehara, Miyako</creatorcontrib><creatorcontrib>Takahashi, Yoko</creatorcontrib><creatorcontrib>Fukagawa, Satoshi</creatorcontrib><creatorcontrib>Miyata, Kouhei</creatorcontrib><creatorcontrib>Kiyoshima, Chihiro</creatorcontrib><creatorcontrib>Yotsumoto, Fusanori</creatorcontrib><creatorcontrib>Anan, Haruchika</creatorcontrib><creatorcontrib>Miyamoto, Shingo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Miyahara, Daisuke</au><au>Katsuta, Takahiro</au><au>Maehara, Miyako</au><au>Takahashi, Yoko</au><au>Fukagawa, Satoshi</au><au>Miyata, Kouhei</au><au>Kiyoshima, Chihiro</au><au>Yotsumoto, Fusanori</au><au>Anan, Haruchika</au><au>Miyamoto, Shingo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>36</volume><issue>7</issue><spage>3725</spage><pages>3725-</pages><eissn>1791-7530</eissn><abstract>Endometrial cancer (EC) has a poor prognosis due to drug resistance.
We evaluated the safety and efficacy of adjuvant combination chemotherapy with docetaxel plus cisplatin ((DP) docetaxel, 70 mg/m(2); cisplatin, 60 mg/m(2); every 28 days) in EC patients at intermediate-risk (IR) or high-risk (HR) for recurrence.
Sixty-four patients diagnosed with EC were enrolled. Stage-I, -II, -III and -IV disease was noted in 23, 7, 28 and 6 patients, respectively. Histopathological analyses revealed that 56, 3, 1 and 4 patients had endometrioid, serous, clear-cell or "other" types of carcinoma. Grade-3/4 hematologic toxicities were found at 80% and 95% in patients in IR and HR groups, respectively. In IR and HR groups, mean progression-free (PFS) survival was 69.5 and 29.5, while overall survival (OS) was 59.6 and 47.5 months, respectively.
DP may be clinically safe and useful treatment for EC.</abstract><cop>Greece</cop><pmid>27354646</pmid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7530 |
| ispartof | Anticancer research, 2016-07, Vol.36 (7), p.3725 |
| issn | 1791-7530 |
| language | eng |
| recordid | cdi_pubmed_primary_27354646 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Endometrioid - drug therapy Carcinoma, Endometrioid - mortality Cisplatin - administration & dosage Disease-Free Survival Drug Administration Schedule Endometrial Neoplasms - drug therapy Endometrial Neoplasms - mortality Female Humans Kaplan-Meier Estimate Middle Aged Proportional Hazards Models Retrospective Studies Risk Taxoids - administration & dosage Treatment Outcome |
| title | Safety and Anti-tumor Effects of Docetaxel Plus Cisplatin in Intermediate- and High-risk Endometrial Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A50%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Anti-tumor%20Effects%20of%20Docetaxel%20Plus%20Cisplatin%20in%20Intermediate-%20and%20High-risk%20Endometrial%20Cancer&rft.jtitle=Anticancer%20research&rft.au=Miyahara,%20Daisuke&rft.date=2016-07-01&rft.volume=36&rft.issue=7&rft.spage=3725&rft.pages=3725-&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cpubmed%3E27354646%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27354646&rfr_iscdi=true |